To compare the efficacy and safety of the once-weekly oral dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes (T2DM) and inadequate glycaemic control on metformin.
insulinotropic polypeptide (GIP), which are part of an endogenous system involved in the physiological regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis in, and release from, pancreatic β cells. GLP-1 also lowers glucagon secretion from pancreatic α cells. The action of these incretins is glucose-dependent, such that when glucose levels are low, enhancement of insulin secretion and inhibition of glucagon release are not observed, a mechanism associated with a low incidence of hypoglycaemia. 1 In the present study, we report the results of a clinical study that compared the glycaemic efficacy and safety of the addition of omarigliptin 25 mg administered once weekly with the addition of sitagliptin 100 mg administered once daily in patients with inadequate glycaemic control on metformin monotherapy.
| MATERIALS AND METHODS

| Patients
Eligible patients were men and women (aged ≥18 years) with T2DM who had been on a stable dose of metformin (≥1500 mg/d) for ≥12 weeks and had a glycated haemoglobin (HbA1c) concentration ≥6.5% and ≤9.0% at screening and a fasting fingerstick glucose >7.2 and <14.4 mmol/L at randomization. Patients were excluded from the study if they had type 1 diabetes, a history of ketoacidosis, active liver disease, significant cardiovascular disease, a history of malignancy or haematological disorders, or if they had been previously treated with any antihyperglycaemic agents other than metformin within 12 weeks prior to screening or with omarigliptin at any time before signing informed consent. For patients assessed by the investigator as possibly having type 1 diabetes, C-peptide level was measured, and patients with a fasting C-peptide level <0.7 ng/mL (0.23 nmol/L) were excluded.
Laboratory exclusion criteria included creatinine levels ≥124 μmol/L (men) or ≥115 μmol/L (women) (≥1. 4 
| Study design
The study was a multinational, double-blind, double-dummy, rando- Figure S1 ). After the run-in period, patients were randomized centrally, using an interactive voice response system, in a 1:1 ratio to omarigliptin 25 mg once weekly (and placebo matching sitagliptin, dosed once daily) or sitagliptin 100 mg once daily (and placebo matching omarigliptin, dosed once weekly 
| Study evaluations
The primary objectives of the present study were assessment of the efficacy, safety and tolerability of 24 weeks of omarigliptin treatment.
The primary study hypothesis was that the mean change from baseline in HbA1c in patients treated with omarigliptin once weekly would be non-inferior to that in patients treated with sitagliptin once daily.
Secondary objectives were to assess the effect of the addition of omarigliptin compared with sitagliptin on FPG and on the percentage of patients with HbA1c of <7.0% and <6.5% after 24 weeks of treatment.
| Efficacy endpoints
Efficacy endpoints were changes from baseline in HbA1c and FPG after 24 weeks of treatment. The percentages of patients who reached HbA1c goals of <7.0% and <6.5% at week 24 were also calculated.
| Safety endpoints
Safety assessment included collection of adverse events (AEs), physical examination, including vital signs, standard laboratory blood chemistry (eg, liver and renal safety tests), lipid panel, haematology, urine analysis and ECG. In addition, amylase and lipase levels were measured as per regulatory agency request. A standard questionnaire was provided to patients to collect hypoglycaemia information.
Potential cases of pancreatitis (events assessed by the investigator as possibly being pancreatitis, or events meeting prespecified event terms suggestive of pancreatitis) and prespecified hypersensitivity AEs (anaphylactic reaction, angioedema, asthma-bronchospasm, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms)
were evaluated in a blinded manner by external clinical adjudication committees.
| Statistical analyses
All randomized patients who received at least one dose of study treatment and had a baseline or a post-randomization measurement served as the primary population for efficacy analyses. For analyses of the primary efficacy endpoint, a constrained longitudinal data analysis (cLDA) model 4 including terms for treatment, time and the interaction of time by treatment with the restriction of a common baseline mean across treatment groups was used. The primary hypothesis regarding the non-inferiority of omarigliptin vs sitagliptin in decreasing HbA1c was assessed using the estimated treatment difference from the cLDA model. If the upper bound of the two-sided 95% confidence interval (CI) for the mean difference between omarigliptin and sitagliptin was less than the non-inferiority margin (δ = 0.3%), then omarigliptin was declared non-inferior to sitagliptin.
Data acquired after the initiation of rescue therapy were treated as missing to avoid the confounding influence of rescue therapy. FPG level was analysed using the cLDA model described above for HbA1c, substituting the FPG baseline efficacy measurement for HbA1c. Analysis of percentages of individuals at the HbA1c goals of <7.0% and <6.5% at week 24 was based on estimated rates and CIs for between-group rate differences computed using the Miettinen and
Nurminen method, 5 stratified by baseline HbA1c (> or ≤ median).
Analysis of safety data used the population of all randomized patients who received at least one dose of study treatment. Safety and tolerability were assessed during the treatment period and through 21 days after treatment, which ended by clinical review of all relevant variables, including AEs, laboratory tests, ECG, vital signs and body weight. Safety data acquired after initiation of glycaemic rescue medication were excluded from the primary analysis. AEs of symptomatic hypoglycaemia were prespecified as events of interest
and P values and 95% CIs for between-treatment group comparisons were calculated. For AEs with incidence of at least 4 patients in any treatment group, change from baseline in body weight, any AE of hypoglycaemia and AEs of severe hypoglycaemia, 95% CIs were calculated for between-group comparisons using the method of Miettinen and Nurminen. 5 For body weight, change from baseline was analysed using the cLDA method described above, substituting baseline body weight for HbA1c.
Using a standard deviation of 0.96% and assuming the true mean difference in HbA1c between omarigliptin and sitagliptin is 0.0% (α = 0.05, two-sided test), and factoring for expected missing data, 300 randomized patients per treatment group would provide 95.7%
power to declare non-inferiority with a margin = 0.3% in HbA1c reduction at week 24.
3 | RESULTS
| Patient disposition and characteristics
A total of 985 patients were screened and 642 were randomized Of the 642 randomized patients, 588 (91.6%) completed the study on study medication ( Figure S2 ). Baseline demographics and efficacy variables were generally balanced between treatment groups (Table 1 ). The mean age was 57.3 years,~50% were male, the mean body mass index was 32 kg/m 2 and the mean duration of diabetes was 7 years.
| Efficacy
After 24 weeks, the LS mean change from baseline in HbA1c was After 24 weeks of treatment, omarigliptin compared with sitagliptin provided a similar reduction in FPG ( Figure 1B and Table 2 ). In both treatment groups, a near-maximum reduction from baseline in FPG was observed at week 6, and the treatment effect was maintained throughout the remainder of the treatment period ( Figure 1B ).
After 24 weeks of treatment, the percentages of patients at HbA1c goals of <7.0% and <6.5% were similar in the two treatment groups. At week 24 the percentages of patients with HbA1c <7.0% Figure S3 ).
Five patients (1.6%) in the omarigliptin group and 6 (1.9%) in the placebo group received rescue therapy at or before week 24 and the time-to-rescue was similar in the 2 treatment groups.
| Safety and tolerability
The incidence rates of overall AEs, AEs assessed by the investigator as drug-related and serious AEs were similar between the omarigliptin and sitagliptin groups (Table 3 ). There were no reported AEs of pancreatitis and no adjudication-confirmed events of pancreatitis in either treatment group. One death attributable to myocardial infarction was reported in a patient in the sitagliptin group; the patient had a history of ischaemic heart disease.
Specific AEs with an incidence ≥2% in ≥1 treatment group are shown in Table 4 . All of the AEs of lipase increased as well as amylase increased (incidence <2%) were non-serious and none led to discontinuation from study medication. One patient in the omarigliptin group had 2 non-serious AEs of tongue oedema, which were not associated with respiratory distress and which were adjudicated and confirmed to be angioedema (a prespecified hypersensitivity AE). The incidence of patients reporting ≥ 1 AE of hypoglycaemia (symptomatic or asymptomatic) was similar in the two treatment groups (Table 3 ). There were no events of hypoglycaemia that required medical assistance; one patient in the omarigliptin group had an event of hypoglycaemia that required non-medical assistance.
There were no clinically meaningful changes from baseline in laboratory safety measures or predefined limits of change. Small increases from baseline at week 24 in mean serum amylase and lipase levels were observed in both treatment groups; the magnitude of the increase was similar in both groups. Both baseline and week 24 mean amylase and lipase values were within normal laboratory limits for both the sitagliptin and omarigliptin groups. At baseline, 11.2% of patients in the omarigliptin group and 11.6% of patients in the sitagliptin group had lipase values greater than the central laboratory upper limit of normal (>ULN).
On treatment, at weeks 6, 12, 18 and 24, the incidence of patients with lipase >ULN ranged from 17.4% to 21.2% in the omarigliptin group and 14.1% to 20.4% in the sitagliptin group (Table S1 ). Lower incidences of amylase >ULN at baseline and on treatment were observed (Table S1 ).
In patients who had a lipase value >ULN at baseline or who had values >ULN during the treatment period, fluctuations above and below the ULN were commonly observed.
There were no clinically meaningful changes from baseline in heart rate, blood pressure or ECG intervals (including QTc). At week 
| DISCUSSION
The present study showed that in patients with T2DM and inade- To convert mmol/L to mg/dL multiply by 18.
percentage of patients with T2DM, which appears to be slightly 1 Difference in % vs sitagliptin; estimate (95% CI) was computed only for those endpoints with at least 4 patients having events in ≥1 treatment groups.
2 Assessed by the investigator as related to study drug.
3 Symptomatic hypoglycaemia: episode with clinical symptoms attributed to hypoglycaemia, without regard to glucose level.
4 P = .515.
5 Asymptomatic hypoglycaemia: glucose values ≤3.9 mmol/L without symptoms. 
